Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | ALPL | P05186 | 10/20 | 0.74 |
| ▸ | CA12 | O43570 | 5/20 | 0.74 |
| ▸ | RPA1 | P27694 | 1/20 | 0.72 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.70 |
| ▸ | RET | P07949 | 1/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.70 |
| ▸ | PIM1 | P11309 | 1/20 | 0.70 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.70 |
| ▸ | GSK3B | P49841 | 1/20 | 0.70 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.70 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.70 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.70 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.70 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.70 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.70 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.70 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27887288 | 0.89 | TP53 (0.79) | TP53ALPLCA12RPA1CHEK1 | |
| Hydrochloric Acid SCHEMBL28800536 | 0.87 | TP53 (0.77) | TP53ALPLCA12RPA1CHEK1 | |
| SCHEMBL2838112 | 0.85 | TP53 (0.73) | TP53ALPLCA12RPA1CHEK1 | |
| SCHEMBL2561357 | 0.85 | TP53 (0.73) | TP53ALPLCA12RPA1CHEK1 | |
| SCHEMBL1414100 | 0.85 | ALPL (1.00) | TP53ALPLCA12RPA1CHEK1 | |
| SCHEMBL222852 | 0.85 | TP53 (0.74) | TP53ALPLCA12RPA1CHEK1 | |
| SCHEMBL10242682 | 0.85 | TP53 (0.74) | TP53ALPLCA12RPA1CHEK1 | |
| SCHEMBL2789578 | 0.85 | TP53 (0.74) | TP53ALPLCA12RPA1CHEK1 | |
| SCHEMBL1816813 | 0.84 | TP53 (0.73) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL23803931 | 0.84 | ALPL (0.73) | TP53ALPLCA12RPA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109111434-A | A kind of Coumarins nickel ion fluorescence probe and preparation method thereof, crystal preparation method and application | 浙江外国语学院 | 2019-01-01 | — | — | CN | claimed |
| EP-2167077-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | claimed |
| EP-2149551-A1 | N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | claimed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | claimed |
| US-20080125463-A1 | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | claimed |
| EP-1903038-A1 | N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | claimed |
| CN-1445218-A | 3-phenyl pyrazole-5-ramification of carboxylic acid derivative as well as its preparing method and medicine appliction | LIU LIGANG (CN) | 2003-10-01 | — | — | CN | claimed |
| EP-3597184-B1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | KOREA RES INST CHEMICAL TECH (KR) | 2026-03-04 | — | — | EP | disclosed |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-11-13 | — | — | US | disclosed |
| US-12378281-B2 | Triterpenone derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2025-08-05 | — | — | US | disclosed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4431505-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2024-09-18 | — | — | EP | disclosed |
| EP-1240136-A1 | USE OF BIOLOGICALLY ACTIVE VITAMIN D COMPOUNDS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE | Northern Lights Pharmaceuticals, LLC (US) | 2002-09-18 | — | — | EP | disclosed |
| US-20020128241-A1 | Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2002-09-12 | — | — | US | disclosed |
| US-6358939-B1 | ADMINISTERING 1,25-DIHYDROXYVITAMIN D TO TREAT ULCERATIVE COLITIS AND CROHN*S DISEASE | NORTHERN LIGHTS PHARMACEUTICALS, LLC | 2002-03-19 | — | — | US | disclosed |
| WO-2001046132-A1 | USE OF BIOLOGICALLY ACTIVE VITAMIN D COMPOUNDS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE | NORTHERN LIGHTS PHARMACEUTICALS, LLC (US) | 2001-06-28 | — | — | WO | disclosed |
| US-5294630-A | Treatment of inflammatory bowel disease | ELI LILLY AND COMPANY (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0578477-A1 | Treatment of inflammatory bowel disease | ELI LILLY AND COMPANY (US) | 1994-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | TP53 4/4885ALPL 4436/4885CA12 1037/4885 |
| US-12378281-B2 | Triterpenone derivatives as HIV inhibitors | CCR5, HSD17B7, CYP51A1 | TP53 3055/4885ALPL 4650/4885CA12 4863/4885 |
| US-20020128241-A1 | Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease | CYP24A1, VDR, SI | TP53 4691/4885ALPL 243/4885CA12 2475/4885 |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | TP53 4864/4885ALPL 4449/4885CA12 4837/4885 |
| US-20080125463-A1 | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | PTGER2, PTGER1, PTGDR2 | TP53 4844/4885ALPL 4427/4885CA12 4805/4885 |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | CRBN, IDH1, IDH2 | TP53 619/4885ALPL 3475/4885CA12 3334/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | TP53 4/4885ALPL 4436/4885CA12 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.